TriLink to open GMP production facility for early phase drugs

摘要

TriLink BioTechnologies, a US manufacturer of oligonucleotides, nucleoside triphosphates and mRNA, says its new 2,000ft~2 diagnostic and pharmaceutical GMP production facility will be fully operational by July. The plant, based in San Diego, CA, will include ISO Class 7 and 8 cleanrooms, designed to facilitate fast turnaround of IND-enabling tox and Phase 0/1 GMP material. TriLink says the facility has been built to meet demand for therapeutic grade GMP mRNA. However, it is fully equipped to manufacture all TriLink products.